Merck putting IT center in Prague; GSK expands API plant in U.K.; Biogen donates hemophilia drugs to developing countries;

@FiercePharma: Allergan board dismisses Valeant bid, but is it running out of options? Report | Follow @FiercePharma

@TracyStaton: Tops online this weekend: Pfizer's move on AstraZeneca outrages pols on two continents. More | Follow @TracyStaton

@EricPFierce: Problems just keep mounting up for Novartis in Japan, this time over events reporting. News | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Pfizer prepares to file for approval with positive PhII MenB data. FierceVaccines story | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) will spend up to £28 million ($47.3 million) to expand a active pharmaceutical ingredient plant in Montrose, U.K. Story

> Japan's Daiichi Sankyo has asked a court in India to withdraw a stay on its sale of Ranbaxy Laboratories to Sun Pharmaceutical that was put in place to allow an investigation into insider trading allegations. Story

> Sanofi ($SNY) is voluntarily recalling three batches of transplant drug Thymoglobuline in the Philippines because of out of specification findings for the product. Story

> Merck ($MRK) will invest about $50 million to create and data analysis center in Prague, Czech Republic that is slated to employ 200 by the end of next year. Story

> Biogen Idec ($BIIB) and Swedish partner Orphan Biovitrum will donate to developing countries over the next decade enough hemophilia drugs to treat tens of thousands of patients. Story

> Danone is negotiating the possible sale of its medical-nutrition business to Nestlé after Fresenius dropped out of the process, sources tell Bloomberg. Story

Medical Device News

@FierceMedDev: Report: Cinven shopping French Dx company Sebia. More | Follow @FierceMedDev

@VarunSaxena2: House votes to make R&D tax credit permanent. What will Senate do? Seems to prefer 2 year extension. Story via WSJ (sub. req.) | Follow @VarunSaxena2

@MichaelGFierce: ICYMI: Double-locked virus needs two enzyme 'keys' to release drugs. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Doctors weigh in on Wikipedia as an evolving--yet flawed--medical text: More from The Atlantic | Follow @EmilyWFierce

> FDA clears prescription video game for rehabilitation therapy. Article

> SI-Bone gets Medicare coverage for its spinal fusion implant. Story

> FDA approves innovative, electrode-powered robotic arm for amputees. News

Biotech News

@FierceBiotech: Show me the money: Which drugs made the top 10 list on upfront deals? Special Report | Follow @FierceBiotech

@JohnCFierce: Lilly draws flak after touting PhIII diabetes success for Lantus rival. More | Follow @JohnCFierce

@DamianFierce: Shire pays $260M for Lumena, getting a rare liver disease treatment and a NASH drug. Story | Follow @DamianFierce

@EmilyMFierce: Potential measles exposure in Fairfax, Loudoun counties investigated. More from The Washington Post | Follow @EmilyMFierce

> Pfizer makes a case for R&D in AstraZeneca megamerger, but does anyone believe it? More

> Chase banks $21M round for Alzheimer's drug research. Item

> Tesaro preps for a Merck showdown after seeing positive PhIII results for rolapitant. Story

CRO News

> Icon wraps up its $143.5M deal for Aptiv. Item

> China's Tigermed buys a $50M stake in a U.S. CRO. Article

> AMRI posts flat revenue as transitional year marches on. More

> Royalty Pharma backs risk-friendly researcher Avillion. Story

> Huntingdon buys Harlan Labs in a bet on CRO growth. Report

Biotech IT News

> Faced with FDA barriers, 23andMe mulls overseas expansion. Item

> U.K. tries to revive 'dead duck' patient data sharing plan. Report

> Debiopharm inks deal with Yale to access computer-aided drug discoveries. Story

> Flatiron raises $130M in Google-led round, buys EMR business. More

> DrugDev buys TrialNetworks to 'glue' its clinical trial apps together. Article

And Finally... A new study shows that by using electrical currents, test patients were able to take control of dreams, like putting on clothes rather than showing up at work naked. Story